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Puromycin aminonucleoside metabolism by glomeruli and glomerular
epithelial cells in vitro. Two puromycin aminonucleoside (PAN) excre-
tion products were purified by HPLC from urine of PAN-treated rats
and characterized by nuclear magnetic resonance as N6-dimethyl-
3'amino-3 'deoxyadenosine (DA-Ado) and N6-methyl-3'amino-3'deoxy-
adenosine (MA-Ado), respectively, the former corresponding to un-
modified PAN. DA-Ado was not a substrate for adenosine deaminase
(ADA), purine nucleoside phosphorylase (PNP) or xanthine oxidase
(XO), while MA-Ado was consecutively converted into hypoxanthine
by a mixture of ADA and PNP. A different rate of transformation of
DA-Ado and MA-Ado into hypoxanthine by isolated glomeruli was
observed and was higher for the monomethylated analogue by a factor
of 3 (79% vs. 21%); this was ascribed to the rate-limiting level of a
demethylase activity acting on DA-Ado. Furthermore, DA-Ado was not
transformed by glomerular epithelial cells in culture, while a little
amount of MA-Ado was converted into hypoxanthine after six hours of
incubation. In spite of this different metabolic behavior, the same order
of cytotoxicity on glomerular epithelial cells in culture was observed for
MA-Ado, DA-Ado and commercial PAN. All these molecules induced
a dose response inhibition of [3H]thymidine incorporation into DNA
after exposure for two hours and a marked alteration of cell viability
which was not inhibited by free radical scavengers and deferoxamine.
This study provides the first evidence for a glomerular metabolism of
PAN and its urinary metabolite MA-Ado involving their transformation
via the purine cycle enzymes. The rate of glomerular transformation of
PAN in isolated glomeruli and the lack of its metabolism in cultured
epithelial cells implies the presence of demethylase enzymes within the
glomerulus and their absence in cultured epithelial cells. However, the
similar cytotoxic effect of PAN and MA-Ado on cultured epithelial cells
supports the concept that a mechanism which does not involve the
purine cycle is responsible for PAN glomerular toxicity in vitro.
The administration of PAN to rats results in massive protein-
uria due to well-defined glomerular lesions which are similar in
many aspects to human minimal change nephropathy [1]. While
the structural defect responsible for proteinuna has been iden-
tified in an alteration of the de novo proteoglycan synthesis by
glomerular epithelial cells [2—4] accompanied by cell detach-
ment [5] and/or in changes of the GBM polyanion composition
[6], little is currently known on the mechanisms responsible for
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them. In recent years a role for toxic oxygen radicals in PAN
nephrotoxicity has been tentatively hypothesized [7—101 on the
basis of a protective effect on proteinuria of superoxide dismu-
tase and of other scavengers such as DMTU [9], benzoate [9]
and polyethylene glycol-conjugated catalase [10]. Other inde-
pendent findings which reinforce the hypothesis of free radical
implication in PAN nephrosis are that proteinuria is reduced by
the iron chelator deferoxamine which inhibits the synthesis of
0H via the Haber-Weiss reaction [9]. The same effect was also
reported when xanthine oxidase was inhibited by allopurinol
[8]. From all these data, a pathogenetic hypothesis has arisen
where PAN is first converted to hypoxanthine within the kidney
and that the successive conversion of hypoxanthine to uric acid
via the xanthine oxidase system is responsible for O genera-
tion [8]. A number of crucial aspects regarding the metabolic
pathway for O generation from PAN remain, however, largely
hypothetical. First of all, the putative metabolic pathway for
transformation of PAN into hypoxanthine within the glomeru-
lus and its potential nephrotoxicity must be clarified, since the
increased supply of hypoxanthine via direct infusion of the base
does not induce proteinuria while being metabolized within the
kidney [11]. In a second instance, the lack of knowledge about
glomerular PAN metabolism contributes in making any consid-
eration on drug renal toxicity unclear and any conclusion
arbitrary. The central questions are whether PAN is metabo-
lized by glomerular cells or not and whether PAN or any of the
PAN metabolites produced in vivo are substrates for enzymes
of the purine cycle (ADA, PNP and XO, the last one being
responsible for the conversion of hypoxanthine to uric acid). All
these crucial points are addressed in this paper.
Methods
Materials
PAN, adenosine deaminase (E.C. 3.5.4.4), purine nucleoside
phosphorylase (E.C. 2.4.2.1), xanthine oxidase (E.C.
1.1.3.2.2), ethylendiaminetetraacetate (EDTA), trypsin inhibi-
tor, dithiothreitol (DTT) were obtained from Sigma (St. Louis,
Missouri, USA); reverse-phase chromatography columns RP18
and preparative Cl8 cartridges Sep-Pack were from Waters
(Milford, Massachusetts, USA). Coomassie G-250 was from
Fluka (Buchs, Switzerland); RPMI 1640 and 199 medium,
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penicillin, streptomycin, L-glutamine and Trypan Blue were
from Flow Laboratories (Milan, Italy); bovine type I collagen,
Vitrogen, was from Collagen Corporation (Palo Alto, Califor-
nia, USA); [3H]thymidine (5 Cilmmol) was from Amersham
(Buckinghamshire, UK); bacterial collagenase was from Wor-
thington (Freehold, New Jersey, USA).
Animal model
Sprague-Dawley/CD male rats (Charles River, Calco, Italy)
weighting 200to 250 g at the start of the experiment were used.
PAN nephrosis was induced by a single injection of PAN (7.5
mgJlOO g dissolved in 0.5 ml of normal saline) through the tail
vein of non-anesthetized animals. Control rats were given
normal saline. In all cases rats were fed a standard diet ad
libitum containing 20% (wt/wt) casein and 2% (wt/wt) trace
elements (non-tungsten) and providing 3,400 kcallkg (Altromin-
Rieper, Vandoies, Italy), and were allowed free access to
water.
Determination and purification of PAN metabolites
Urine samples were deproteinized by precipitation with 12%
tnchloracetic acid (1:5 vollvol) at 4°C for 15 minutes, followed
by protein removal by centrifugation at 2,000 g (15 mm, 4°C)
and neutralization by KOH 2 M. An HPLC system was used to
separate and determine PAN metabolites, consisting in a re-
verse-phase column (C 18) working at room temperature and
employing a three-step mobile phase: (1) constant 0.025 molt
liter KH2PO4 pH 5 with a flow rate of 1 mI/mm for 15 minutes;
(2) a linear gradient between phase 1 and 30% (vol/vol) metha-
nol for 20 minutes with a 1 mI/mm flow rate; and (3) constant
0.025 mol/liter KH2PO4 30% (vol/vol) methanol for 15 minutes
with a I mllmin flow rate. A variable wavelength visible, U.V.
detector was employed to analyze the spectral characteristics of
eluted metabolites whose concentrations were calculated by
comparison with a standard sample of PAN of known concen-
tration. The same apparatus was employed for purification of
every single metabolite, and each was further processed by
preparative reverse-phase chromatography on a C 18 Sep-Pack
column working at room temperature, and pretreated with 10 ml
of 100% (vol/vol) methanol followed by 10 ml H20. After
sample loading (4 ml), the separation was developed by 4 ml
H20 (to eliminate salts), and 2 ml 100% methanol in which
phase every single metabolite was eluted. Purity was tested by
HPLC as described above.
Determination of hypoxanthine, xanthine and uric acid
Hypoxanthine and xanthine were determined by reverse-
phase HPLC under the same conditions used for PAN metab-
olites. Uric acid was determined by a previously-reported
enzymatic assay [11].
NMR spectra
'H-NMR spectra were obtained with a Bruker AM-270 spec-
trometer, controlled by an Aspect 3000 Computer. The 2D-
COSY spectrum was acquired with a sweep width of 1800 Hz
over 2K data points and resolution-enhancement was obtained
with a ir/3-shifted squared sine-bell in both dimensions. Chem-
ical shifts were given in ppm from sodium 3-trimethylsilyl
(2,2,3,3-2H4) propionate (TSP). Assignments of proton spectra
of the two urinary compounds were done by comparison with
the spectrum of commercial PAN.
ADA, PNP and XO determination
ADA activity was assayed spectrophotometrically at 265 nm,
using as substrate 0.1 ms adenosine in 0.1 M Tris-HC1 buffer,
pH 7.4. PNP activity was assayed spectrophometrically at 293
nm, in the presence of excess commercial xanthine oxidase,
using as substrate 0.9 mM inosine in 0.1 M Tris-phosphate
buffer, pH 7.4. XO activity was assayed spectrophotometrically
at 293 nm, using as substrate 0.9 mrvi hypoxanthine in 0.1 M
Tris-HCI buffer, pH 7.4. All assays were performed at 37°C in 1
ml reaction mixtures.
Tests with enzymes
Fractions purified by HPLC as described above, starting
from the urine of rats treated with PAN, were challenged with
some purine metabolizing enzymes: adenosine deaminase
(ADA), nucleoside phosphorylase (PNP) and xanthine oxidase
(XO). The assay was carried out with commercial enzymes in
0.15 M Tns-phosphate buffer pH 7.4 at 25°C. The reaction
mixture contained, in a final volume of 1 ml, 50 nmol of the
tested compound and 1 enzyme unit of each enzyme. Reactions
were monitored both by recording spectra between 300 and 240
nm every minute over a 10 minute interval and by injection in
the HPLC apparatus (under the conditions specified above) at
the end of a one hour incubation period.
Isolation of glomeruli
Glomeruli were isolated from Sprague-DawleytCD male rats
by a differential sieving technique according to standard meth-
ods [12]. Sprague-Dawley rats weighing 150 to 180 g were
anesthetized with Ketalar (30 mg/kg). After clamping the aorta,
the renal veins were cut and kidneys were perfused with
ice-cold 0.9% NaCI containing 1 mrt EDTA, 0.2 m PMSF, I
mM DTT, 5 g/ml trypsin inhibitor and 2 U/ml Trasylol, and
kidneys were removed after blanching. The dissected cortex
was then minced with a razor blade in PBS containing the same
protease inhibitors and gently squeezed through a stainless steel
sieve (250 pm). The resulting suspension was filtered through a
150 pm sieve and was washed three times in HBSS. Centrifuged
glomeruli were finally collected on the top of a 75 sm sieve. The
retained glomeruli were rinsed in PBS and tested by micros-
copy: only preparations with > 95% glomeruli were used. The
glomerular suspension was centrifuged at 150 .g for five min-
utes and resuspended in a small volume of 50 msi Tris-HCI
buffer, pH 7.5, containing protease inhibitors. After disruption
of cellular structures by sonication, protein content was deter-
mined using the Coomassie dye binding assay [13].
Cell culture
Glomerular epithelial cells were cultured starting from puri-
fled glomeruli obtained from Sprague-Dawley rats (150 to 180 g)
and killed with a lethal dose of sodium pentobarbital. Glomeruli
isolated by the sieving technique (see above) under sterile
conditions were resuspended in 199 medium supplemented with
10% fetal calf serum (FCS), 2.2 g/liter sodium bicarbonate, 2
mmol/liter glutamine, 100 U/ml penicillin, 100 g/ml streptomy-
cm and 0.18 U/mI insulin. They were then plated onto 25-sq cm
Falcon tissue culture flasks, previously coated with a thin film
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of collagen and maintained at 37°C in humidified 5% CO2
atmosphere. Cultured cells were recognized as epithelial [14]
from: (1) typical cobblestone-like morphology and polygonal
shape; (2) early outgrowth; (3) absence of factor VIII as
determined by double immunofluorescent technique; (4) posi-
tivity for cytokeratin. To avoid mesangial cell contamination,
only cells obtained from the primary culture (ito 2 weeks) were
used. Mesangial cells were recognized from epithelial cells
based on the following criteria: (1) morphology; (2) negative
staining by indirect immunofluorescence for cytokeratin; (3)
contractile response to angiotensin II. Cells deriving from the
second or third subculture were used.
incubations
Incubations of glomeruli homogenates (protein content: 2
mg/mi) and GEC (l0 cells under a 5% CO2 atmosphere) with
commercial PAN and PAN metabolites were performed at 37°C
in 0.05 M Tris-HCI buffer pH 7.5, containing 1 mri EDTA, 0.2
mM PMSF, 1 mri DTT and 5 g/ml trypsin inhibitor. Freshly
prepared glomeruli were dissolved in 0.05 M Tris-HCI buffer
and sonicated at 0°C until complete tissue disruption. Equimo-
lar (1 mmol/liter) concentrations of PAN or PAN metabolites
(PAN-Sigma, DA-Ado and MA-Ado) were added to experimen-
tal tubes. The control tube received buffer in equal volume. A
total of 0.3 mri NADPH was added in the test tubes. In a typical
experiment, incubation was continued for two hours in a final
volume of 500 l and was then stopped by adding 500 jsl of
ice-cold 10% trichloracetic acid. After 20 minutes, samples
were centrifuged for 20 minutes at 2,000. g. Following neutral-
ization with 2 M KOH, the supernatant was injected in the
HPLC apparatus.
Cytotoxicity assays
After exposure to PAN or DA-Ado or MA-Ado, [3H] thymi-
dine incorporation by GEC was evaluated by incubating iO
cells with 5 sCilml [3H]thymidine for 24 hours at 37°C in a 5%
CO2 atmosphere. Dose response curves for PAN toxicity were
performed by incubating PAN in several concentrations from
0.1 to 2 mrt. Free radical scavengers (Allopurinol 1 mM;
Catalase 2,000 U/mI) were preincubated with cells for two hours
to permit their free passage within the cell, and were removed
prior to the addition of PAN. In the case of deferoxamine, cells
were preincubated with iron chelator (1 to 5 mM) for four hours
by the method according to Gannon et al [15]. On completion of
the drug exposure, cells were washed twice and resuspended in
fresh medium. After extensive washing in RPM!, cells were
counted in a Packard 13-scintillation counter after being trans-
ferred under vacuum to filter paper sheets, and were solubilized
in filter count scintillation fluid. All determinations were per-
formed in triplicate. For measurement of cell viability, the
Trypan-blue dye exclusion test was employed [16]. Cultures
were harvested in 0.05% trypsin - 0.02% EDTA and stained
with 0.05% Trypan blue for five minutes. The percent of cells
excluding the dye was then evaluated by direct counting in a
hemocytometer.
Other methods
The Coomassie dye binding assay [13] was employed to
evaluate proteinuria.
Statistical analysis
The one-way analysis of variance was used in all statistical
tests. Results are given as mean SE.
Results
Purification and characterization of PAN metabolites from
rat urine
Two chromatographic peaks, corresponding to PAN ana-
logues, were isolated from urine of PAN-treated rats by reverse
phase HPLC. The slower one had the same chromatographic
and optical (absorbance maximum at 275 nm) properties of
unmodified PAN, while the faster one eluted before PAN and
presented an absorbance maximum at 266 nm. The two peaks
were purified by preparative reverse-phase HPLC and were
characterized by NMR. Spectral characteristics and structural
assignment are reported in Figure 1 and in Table 1. By compar-
ing the spectra from PAN, two main features were observed: (1)
the intensity of the methyl group corresponded to six protons in
PAN and in the slower peak, while to three protons in the other,
indicating the presence of only one moiety; (2) the chemical
shifts of protons H2 and H8 were slightly different between the
two purified metabolites, the major one corresponding to PAN.
The slower peak corresponded to the N6-dimethyl-3'amino-
3'deoxyadenosine and was therefore labeled as "DA-Ado".
The faster peak, on the other hand, contained the monometh-
ylated form of this molecule, namely N6-methyl-3'amino-
3'deoxyadenosine, and was labeled as "MA-Ado".
Urinary excretion of DA-Ado and MA-Ado
The rate of urinary excretion of both metabolites are reported
in Figure 2 and in Table 2, respectively. As shown, DA-Ado and
MA-Ado were rapidly (within 6 hr) excreted into urine, and no
trace of either peak was found in urine after 24 hours. The total
amount of PAN excreted into urine in the 24 hours following
PAN treatment in the form of unmodified molecule (DA-Ado),
and MA-Ado was the 50% of the injected compound. The main
fraction (DA-Ado) roughly corresponded to the 70% of the total
urinary excretion.
in vitro metabolism of PAN and PAN products by purine
cycle enzymes
Activities of the purine cycle enzymes, ADA, PNP and XO,
on commercial PAN and its urinary products DA-Ado and
MA-Ado are shown in Table 3. While in this in vitro system
commercial PAN and DA-Ado were not substrates for any of
the three enzymes or for a mixture of them, MA-Ado was
transformed by ADA in a product (presumably 3'-amino-
3'deoxy-ribosylhypoxanthine) which in turn was transformed
by PNP into hypoxanthine and eventually into urate by XO.
This transformation by the in vitro system of MA-Ado into
urate was complete within one hour of incubation at 25°C. Any
other combination of enzyme activity not following the scheme
ADA—*PNP--XO did not produce any change in MA-Ado
(Table 4).
Metabolism of PAN and PAN products by isolated glomeruli
and glomerular epithelial cells in culture
We first investigated whether isolated glomeruli contained
the enzymes of the purine cycle. Secondly we focused on the
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Table 1. Chemical shifts in ppm relative to TSP (sodium 3-
trimethylsilyl (2,2,3,3-2H4) propionate
PAN DA-Ado MA-Ado
H-8 8.08 8.13 8.15
H-2 7.92 8.02 8.11
H-I 5.90 5.99 6.00
H-2 not observed 4.82 4.81
H-4 4.45 4.32 4.28
H-3 3.99 3.94 3.92
H-5 3.88 3.88 3.87
H-5' 3.71 3.73 3.72
Me 3.20 3.28 2.97
Me indicates the methyl group.
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
PPM
I I I I I-I -
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0
PPM
Flg L NMR spectra and structure assignment for PAN and the two
urinary analogs. The structural assignment of each peak are shown in
Table 1. (*) Indicates the presence of impurities.
glomerular metabolism of PAN and related products. In gb-
meruli, all three enzymes which constituted the in vitro system
acting on MA-Ado were present (Table 5). The specific activity
of these enzymes followed the same pattern already described
for renal homogenates [17, 18], and for other organs such as
heart and liver where PNP level is 1.5 times the ADA levels and
is higher compared to XO by a factor of 30. Due to this fact,
MA-Ado was efficiently converted into hypoxanthine (79%
decrement of MA-Ado and 79% increment of hypoxanthine)
upon incubation for six hours (Table 4). This metabolic rate was
consistently lower in the presence of cultured GEC where only
10% of MA-Ado was converted into hypoxanthine. Interest-
rats
Analog N mg124 hr
% of
injected
PAN
MA-Ado 13 1.95 0.22 10.6 1.1
DA-Ado 13 6.71 0.93 36.3 4.7
Total 8.66 1.09 46.9 6.1
ingly, DA-Ado was also metabolized by isolated glomeruli,
about 20% of this compound being converted to hypoxanthine,
while (as already shown above) no metabolism of Da-Ado was
achieved with a mixture of PNP and ADA in vitro (Table 4).
This suggests the presence of demethylase enzymes within the
glomerulus which would convert PAN (or DA-Ado) into MA-
Ado. As for MA-Ado, GEC are not the site for DA-Ado
transformation in spite of the fact that a considerable amount
(>50%) of both molecules entered the cells. Figure 3 shows the
time-dependent transformation of PAN and DA-Ado into hy-
poxanthine with isolated glomeruli; more than four hours elapse
before the appearance of PAN metabolites.
In vitro cytotoxicity
In vitro cytotoxicity of PAN and its analogues on cultured
GEC was investigated by two tests: the former, based on
B DA-Ado
3.5 3.0
C MA-Ado
100
cD
C-,x
a,
2 500
Time, hours from PAN
Fig. 2. Urinary excretion of DA-Ado (O—O) and MA-Ado (S 5)
following administration of PAN to rats. Results are given as percent of
the total urinary excretion of each metabolite.
Table 2. Urinary excretion of the two major analogs of PAN, DA-
Ado and MA-Ado in the 24 hours which followed PAN injection in
0 3 6 12 18 24
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Commercial
enzyme
Activity relative to adenosine or inosine
PAN DA-Ado MA-Ado 3'NH2-RHx
ADA 0 0 3.6. lO —
PNP 0 0 0 0.012
XO 0 0 0 0
Invitro
system
PA
%
Hypo
N
%
PAN
DA-
%
Hypo
Ado
%
DA-Ado
MA
%
Hypo
-Ado
%
MA-Ado
ADA 0 0 0 0 0 0
PNP 0 0 0 0 0 0
ADA+ 0 0 0 0 +100 —100
PNP
Isolated
glomerulib +21 —21 +21 —21 +79 79(N=4)
Cultured
podocytese 0 0 0 0 0 0
(N = 4)
Table 5. Enzymatic acti
nucleoside phosphor
i
vities of adenosine deaminase (ADA), purine
ylase (PNP) and xanthine oxidase (XO) in
solated rat glomeruli
N Enzymatic activity EU mg'
ADA 3 0.093
PNP3 0.13 0.01
X03 0.5. iO 0.01
24-hour [3H]thymidine incorporation into DNA, was planned to
assess the acute effects of aminonucleosides; the second test
was aimed more directly at analyzing the long-term effect on
cell viability. Both tests demonstrated a marked cytotoxic effect
of all molecules which induced comparable inhibitory effects on
[3H]thytnidine incorporation into GEC DNA and on cell viabil-
ity (Table 6). The dose-response cytotoxicity curve of PAN and
related metabolites on GEC is shown in Table 7. Here it appears
that even the lower dose of PAN (0.1 mM) was able to inhibit
DNA synthesis by 50%, as well as DA-Ado and MA-Ado. In no
case did the use of allopurinol and catalase as free radical
scavengers and of the iron chelator deferoxamine show any
protective effect against PAN induced cytotoxicity (Table 7).
Discussion
Recent hypotheses on a role for free oxygen radicals in
PAN-induced proteinuria were based on a protective effect of
Treatment
[3H]Thymidine
incorporation
cpmIlO4 cells
Cell viability
% of total cells
I day 5 days
None 10,400 600 (100%) 97 1% 76 1%
1mM PAN 1,040 110 (10%) 77 9% 34 1%a
1 mM DA-Ado 1,476 72 (14.2%)a 80 4%° 40 2%°
I m MA-Ado 1,248 24 (12%)° 82 2%° 36 4%°
1 mM Hypoxanthine 10,000 351 (100%) 96 6% 79 3%
scavengers such as DMTU, benzoate, SOD and PEG-conju-
gated catalase [7—10]. Moreover, the protective effect of the
iron chelator deferoxamine [9] suggested that iron is critical in
the generation of free radicals from PAN, lending credence to
the idea that 0H arises from 0 via the Haber-Weiss reaction
[19]. The central point regarding the mechanism(s) of glomeru-
lar toxicity by PAN, which is so far unresolved, is the question
on the metabolic pathway generating O from PAN which
should be reasonably active within the glomerulus due to the
very short lifetime (in the order of milliseconds) of the impli-
cated radicals. The most favored hypothesis, proposed by
Diamond, Bonventre and Karnovski [8] states that hypoxan-
thine, a minor putative metabolite of PAN [21], represents the
source of O via the xanthine oxidase system which transforms
hypoxanthine into xanthine and uric acid. Preliminary studies
on free radical generation from PAN by GEC in vitro have also
provided the theoretical support for this possibility [20].
Too little is currently known about the general metabolism of
PAN in rats, and more specifically about the glomerulus as the
site of PAN transformation, to tempt any alternative interpre-
tation. This study was therefore designed to define the meta-
bolic pathways within the glomerulus for PAN and its major
metabolic products. The data reported confirm previous obser-
Table 3. Activities of the purine cycle enzymes, ADA, PNP and XO
on PAN and on the related products, DA-Ado and MA-Ado, purified
from urine of PAN-treated rats
3'NH2-RHx (3'NH2-ribosyl hypoxanthine) indicates the product of
transformation of MA-Ado by ADA.
Table 4. In vitro metabolism of PAN and of its urinary products,
DA-Ado and MA-Ado, purified from rats treated with PAN, as
evaluated by HPLC analysis after incubation with the appropriate
enzyme system
20
10oa.
>-.--
0
Time, hours of incubation
Fig. 3. Rate of glomerular hypoxanthine production from PAN(• •) and DA-Ado (O—O) as a function of incubation time.
Results are given as percent of the initial amount of substrate on a molar
basis.
Table 6. In vitro cytotoxicity on GEC by PAN and its urinary
products DA-Ado and MA-Ado
012 4 6 8 12
a One hr incubation at 25°C in 0. I M phosphate buffer pH 7.4b Six hr incubation at 37°C in 0.1 54 phosphate buffer pH 7.4 in the
presence of 0.3 msi NADPH
Six hr incubation with io cells
Twenty-four-hour [3H]thymidine incorporation was evaluated after
incubating cells for 2 hours in the presence of each compound. Cell
viability was evaluated by the Trypan-Blue dye exclusion test.
a P < 0.001 vs. control cells (no treatment)
Data are given as enzymatic units per milligram of protein.
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Table 7. Dose-response of in vitro cytotoxicity on GEC by PAN
metabolites
[3H] Thymidine incorporation
Treatment cpm/1O/ce11s
None (5) 9,851 632 (100%)
0.1 mM PAN (5) 5,221 131 (53%)
0.5 mM PAN (4) 3,940 262 (40%)
1 mM PAN (4) 988 56 (10%)
2 mat PAN (4) 838 21(8.5%)
0.5 mM PAN + Def(4) 4,137 231 (42%)
0.5 flM PAN + Allo (4) 3,546 128 (36%)
0.5 mM PAN + Cat (4) 3,841 323 (39%)
1 mM PAN + Def(5) 1,182 63 (12%)
1 mM PAN + Allo (5) 1,083 89 (11%)
1 mM PAN + Cat (4) 830 10 (9%)
0.1 mM DA-ADO (2) 5,810 60 (59%)
1 mM DA-ADO (2) 1,398 220 (14.2%)
0.1 mM MA-ADO (2) 5,122 280 (52%)
1 mM MA-ADO (2) 1,180 100 (12%)
Several free radical scavengers were employed for tentatively block
the cytotoxicity of PAN. Abbreviations are: Def, deferoxamine; Alto,
allopurinol; Cat, catalase.
vations demonstrating that no more than 50% of injected PAN
is excreted into urine [21, 22], and give for the first time
spectroscopic evidence for the in vivo formation of a urinary
metabolite which corresponds to the monomethyl derivative.
Both unmodified PAN and its monomethyl derivate are exten-
sively cytotoxic on cultured GEC in vitro when evaluated by
[3Hlthymidine incorporation into DNA and by the Trypan blue
exclusion test, with an order of toxicity greater for the mono-
methylated analogue compared to the dimethylated form. Al-
though these measures of cytotoxicity may not reflect the
precise mechanisms that are responsible for proteinuria, they
have been widely employed in the past and represent reliable
markers of toxicity in vitro [16]. From other studies, glomerular
epithelial cells have been shown to be the target of PAN
cytotoxicity in vitro where it produces focal detachment of
cells, alteration in polyanions synthesis and changes in the
turnover of glucosamine [23]. All these changes are considered
to be the main pathogenetic factor in determining proteinuria in
this model of nephropathy [24].
The primary finding reported in this study is that both PAN
derivatives can be partially metabolized within the glomerulus
in relation to the presence of one or two methyl groups at N6. A
scheme of the pathway for transformation of both DA-Ado and
its monomethylated analogue is shown in Figure 4, which sums
up the in vitro data obtained from an artificial metabolic
pathway and from isolated glomeruli. In the presence of gb-
merular homogenates, both metabolites are partially converted
to hypoxanthine. Quantitative evaluation of the data, however,
shows that in gbomeruli the rate-limiting factor for the metabo-
lization of the dimethyl compound is the first step, relative to
formation of the monomethylated analogue by a demethylase
activity. Indeed, due to the high level of both PNP and ADA
specific activities, conversion of MA-Ado to hypoxanthine is
not expected to be a rate-limiting step in the overall scheme.
These data strongly support the concept that some PAN is
transformed by glomerular homogenates into the precursors of
uric acid, but the main quota of this molecule is not transformed
by renal tissue. The lack of conversion of PAN into hypoxan-
thine by GEC suggests the absence of demethylases in these
cells, which could also possibly be due to an in vitro artifact. In
any case, PAN may be converted in vivo by endothelial or
mesangial cells which may contain demethylase. All these
points raise important questions about the mechanism for PAN
toxicity in vivo. If in fact we stress the concept that PAN is
actively cytotoxic on the kidney through its monomethylated
analogue following transformation to substrates for the XO
system (hypoxanthine and xanthine) to be converted into uric
acid, the block of the rate limiting enzyme for this metabolic
pathway, namely the demethylase, should confer protection
against proteinuna in this model. Data in the literature are
unfortunately quite confusing and do not permit a definite
conclusion. The three following points speak against any impli-
cation of the glomerular metabolism of PAN via the punne
cycle enzymes as a source of nephrotoxic compound: (1) in vivo
inhibition of microsomal N-demethylase (cytochrome P-450) by
a-naphthylisothiocyanate or SKF-525A did not reduce protein-
uria in PAN treated rats [25]; (2) the mechanism of action of
PAN in vivo is very fast [1] (a matter of a few minutes) while in
vitro conversion of PAN into hypoxanthine within the glomer-
ulus employs several hours (more than 2 hours); (3) hypoxan-
thine is not directly cytotoxic on cultured podocytes in vitro,
even when given in very high doses to overload the intracellular
compartment (data reported here). Furthermore, studies on the
mechanism of PAN action in vivo and in vitro have revealed
that some structural analogues of PAN containing a 3'-hydroxyl
group, such as N6-methyl- and N6-dimethyl-adenosine are
active blockers of PAN nephrotoxicity through competition at
the target of aminonucleoside action and/or of its cellular
uptake [25, 26]. The former molecule is a substrate for ADA and
is eventually transformed to hypoxanthine in vitro at rate at
least similar to that of MA-Ado, thus excluding any direct
implication of this pathway in nephrotoxicity. This point needs,
however, further study which should point out the effectiveness
of demethylase inhibitors at the cellular level as blockers of
PAN toxicity in vitro. In spite of the uncertainties about the in
vivo mechanism of PAN toxicity, some conclusions on the in
vitro mechanism of cytotoxicity may be reached. The occur-
rence of PAN toxicity on GEC without conversion into hypox-
anthine implies that alternative mechanisms for the inhibition of
DNA synthesis and successive cellular death are active in this
condition. The lack of a protective effect on PAN cytotoxicity
by free radical scavengers or by a potent inhibitor of OW
formation, such as the iron chelator deferoxamine, also sup-
ports this view. Determining the mechanism responsible for
PAN cytotoxicity that does not involve the purine cycle metab-
olism was beyond the scope of this work, however, on a
theoretical ground we hypothesize that it may be ascribed to a
general effect of PAN analogs on protein synthesis [27]. PAN is,
in fact, able to interrupt the peptide chain elongation during
protein synthesis in ribosomes, by virtue of the capacity to
react with peptidyl-RNA, a reaction which yields peptidyl-PAN
[27].
In summary, the data reported here provide the first evidence
for a glomerular metabolism of PAN and its urinary products,
DA-Ado and MA-Ado, involving their transformation via the
purine cycle enzymes. The slow rate of transformation of
DA-Ado by isolated glomeruli and the lack of its metabolism by
(1) (2)
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(3)
CH3
1/202 CH2O N(\ H20 CH3NH2 H\)\ NN
Demethylase
HOCH2 I
NH2 OH
cultured GEC implies the presence of demethylase enzymes
within the glomerulus and their absence in cultured GEC. The
similar cytotoxic effect of commercial PAN, DA-Ado and
MA-Ado on these cells supports the concept that a different
mechanism, not involving transformation of these compounds
into hypoxanthine via the purine cycle enzymes, is responsible
for its glomerular toxicity in vitro.
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